Articles

Immunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in Frontiers

Immunomic Therapeutics' Prakash Koodathingal, Director of RNA Therapeutics Development, shares his insight into CQAs for saRNA for GEN magazine's "Expansion of the RNA Technology Universe." Read the full article here:

July 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how a

In the Washington Post article "How Jimmy Carter boosted a life-saving cancer drug," our scientific advisor Dr. Drew Pardoll provides his outlook on Carter's impact on immune therapy. Pardoll, the

The article "Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic," authored by our academic collaborator, Dr. Duane Mitchell was released in AACR's journal of Clinical Cancer Research on March

https://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/

Immunomic Therapeutics highlighted in Washington Business Journal as a life sciences leader in Maryland’s Montgomery County: The Immunology Capital Next to the Nation’s Capital. Click here to read more: http://ow.ly/NQrc50IVzkT

Claire Rosean, Senior Scientist discusses ITI-3000, First-In-Human Trial for Merkel Cell Carcinoma and the preclinical data presented at AACR. Click below to watch the full interview: https://www.oncologytube.com/video/40935/claire-rosean-phd-immunomix-uw-aacr22-mcc-iti-3000-first-in-human-trial?channelName=AACR 

Read the latest Washington Business Journal article highlighting Immunomic Therapeutics by clicking the link below: https://www.bizjournals.com/washington/news/2022/03/17/immunomic-therapeutics-expanding-hiring-pre-ipo.html

Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led

Bill Hearl joins BioTalk host Rich Bendis to discuss their recent successes in funding, research, and their growth in the BioHealth Capital Region Dr. William Hearl is the founder of

Please read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics.